English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The platelet glycoprotein GPIIb/IIIa ( a IIb b 3 ) antagonist c7E3 Fab (the Fab fragment of the mouse/human chimeric monoclonal antibody 7E3; abciximab; ReoProTM) was approved for human use in the United States in December 1994 based on its safety and its efficacy in reducing the risk of ischemic complications after percutaneous coronary intervention (PCI; 1 angioplasty or atherectomy) (1, 2). The success of this agent reflects our emerging ability to identify adhesion molecules as therapeutic targets, and then construct effective inhibitors that meet the stringent safety standards required for a new drug. As the first rationally designed antiplatelet and anti-integrin receptor drug, c7E3 Fab serves as a prototype for other anti-integrin receptor, and more generally, antiadhesion receptor, agents designed to treat and/or prevent human disease.

Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.